DEF: Xtant Medical Seeks Equity Plan Expansion, Board Elections

Xtant Medical Holdings, Inc. announces its 2025 Annual Meeting agenda, including director elections, auditor ratification, and a significant increase in its equity incentive plan share reserve.

Summary

• The Annual Meeting of Stockholders will be held on November 7, 2025, at 8:00 a.m. Eastern Time, at the offices of Fox Rothschild LLP in New York.
• Stockholders will vote on the election of six director nominees, including new appointees Abhinav Jain and Tyler P. Lipschultz.
• A proposal to ratify the appointment of Grant Thornton LLP as the independent registered public accounting firm for the year ending December 31, 2025, will be voted upon.
• Stockholders are asked to approve an amendment to the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan to increase the number of shares available by 12,300,000, bringing the total to 17,800,000 shares.
• Advisory (non-binding) votes on executive officer compensation and the frequency of future advisory votes on executive compensation (Board recommends annually) are also on the agenda.
• For fiscal year 2024, the company reported a net loss of $16,449 (in thousands) and executive officers did not receive annual bonuses.
• The company's common stock outstanding as of September 9, 2025, was 140,000,485 shares.
• Current dilution from outstanding equity awards is 6.9%, with potential dilution rising to 18.7% if the proposed equity plan amendment is approved.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the reported net loss for 2024, the absence of executive bonuses, and the significant potential dilution from the proposed equity plan expansion. While there are positive governance updates and strategic board appointments, the financial performance and dilution concerns weigh heavily.

Positives

• The proposed amendment to the 2023 Equity Incentive Plan includes sound governance features such as no automatic share replenishment, no re-pricing of underwater options without stockholder approval, and limits on non-employee director compensation.
• The Board recommends an annual frequency for future advisory votes on executive compensation, aligning with common stockholder preferences.
• The executive compensation program is designed to attract, retain, motivate, and reward highly qualified executive officers, emphasizing long-term performance and aligning interests with stockholders.
• The company has adopted a clawback policy (effective October 1, 2023) and an anti-hedging and anti-pledging policy, enhancing corporate governance.

Negatives

• Executive officers did not receive any annual bonuses for 2024 performance, indicating a failure to meet pre-established corporate objectives.
• The company reported a net loss of $16,449 (in thousands) for the fiscal year ended December 31, 2024.
• The total stockholder return for 2024 was negative, with an initial $100 investment decreasing to $78.57.
• The proposed increase of 12,300,000 shares to the equity incentive plan could lead to a potential dilution (overhang) of 18.7% of shares outstanding, up from a current dilution of 6.9%.

Risks

• The company faces regulatory, compliance, legal, competitive, financial (accounting, credit, interest rate, liquidity, and tax), operational, political, strategic, and reputational risks.
• Potential dilution of existing stockholder value due to the significant increase in shares available for issuance under the amended equity incentive plan.
• Tax implications for participants and the company related to equity awards, including potential 20% penalty tax under Section 409A of the Code and limitations on deductibility under Section 162(m) of the Code.
• Potential excise tax on parachute payments under Section 4999 of the Code in the event of a change in control.

Future Outlook

The company expects the additional shares available under the Amended 2023 Equity Incentive Plan to cover awards for approximately two years, though this is subject to future equity grant practices, stock price, and hiring activity. The Board expects to conduct advisory votes on executive compensation annually, with the next frequency vote anticipated in 2031.

Management Comments

• The Board believes the current leadership structure, with Stavros G. Vizirgianakis as Chair and Sean E. Browne as President and CEO, is in the best interests of the Company and its stockholders, striking an appropriate balance between strategic direction and day-to-day leadership.
• The Board believes that the executive compensation program is competitive, focused on pay for performance, and strongly aligned with the long-term interests of stockholders, and that 2024 executive compensation was reasonable, appropriate, and justified by company performance.

Industry Context

Operating within the medical device and medtech sectors, Xtant Medical Holdings, Inc. utilizes market data and a peer group of similar companies (e.g., Anika Therapeutics, AxoGen, OrthoPediatrics Corp., Treace Medical Concepts, Inc.) to benchmark its executive compensation program. The company's focus on equity-based incentives and long-term performance aligns with common practices in the competitive medical technology industry to attract and retain specialized talent.

Comparison to Industry Standards

• The company targets executive compensation at the 50th percentile of its peer group, which includes Anika Therapeutics, Inc., AxoGen, Inc., Iradimed Corporation, NeuroPace, Inc., OrthoPediatrics Corp., Pulmonx Corporation, Rockwell Medical, Inc., Sanara MedTech Inc., SI-BONE, Inc., Sientra, Inc., Sight Sciences, Inc., Silk Road Medical, Inc., Surmodics, Inc., TELA Bio, Inc., Treace Medical Concepts, Inc., and Zynex, Inc.
• The three-year average burn rate (2022-2024) for equity awards is approximately 3.6%, which is a metric often compared against industry averages to assess dilution and share usage efficiency.

Management Changes

Corporate Governance

Related Party Transactions

• On April 10, 2025, OrbiMed Sellers (affiliates of OrbiMed Advisors LLC, former majority stockholders) sold 73,114,592 shares of common stock to funds affiliated with Nantahala Capital Management, LLC, Carol Ann Vizirgianakis (mother of Board Chair Stavros G. Vizirgianakis), and other purchasers.
• To facilitate the OrbiMed share sale, the company entered into a registration rights agreement with the purchasers, agreeing to register the resale of shares and indemnify selling stockholders.
• The Investor Rights Agreement with OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP, which granted certain governance and director nomination rights, was terminated on April 15, 2025, following their sale of shares.
• Abhinav Jain and Tyler P. Lipschultz were appointed to the Board on August 1, 2025, at the request of Nantahala Capital Management, LLC, which became a beneficial owner of 49.1% of outstanding common stock.
• A prior agreement with Stavros G. Vizirgianakis, as lead investor of the 2022 private placement, which provided him with director nomination rights, terminated on October 7, 2024.

Stakeholder Impact

• Shareholders: Potential dilution from the expanded equity incentive plan, but also benefit from enhanced corporate governance policies (clawback, anti-hedging) and strategic board appointments aimed at long-term value.
• Employees: The expanded equity incentive plan provides continued opportunities for stock-based compensation, crucial for attraction and retention, but no annual bonuses were paid for 2024 performance.
• Directors: Changes in board composition and committee assignments, with new directors appointed at the request of a significant shareholder, and director compensation includes cash retainers and equity grants.
• Management: Executive compensation is tied to long-term performance, but 2024 saw no annual bonuses. Employment agreements include severance provisions.

Next Steps

• Stockholders will vote on the proposed agenda items at the Annual Meeting on November 7, 2025.
• The company will announce preliminary voting results at the Annual Meeting and disclose final results in a Current Report on Form 8-K within four business days.
• The next advisory vote on executive compensation is expected at the 2026 Annual Meeting of Stockholders.
• The next advisory vote on the frequency of future advisory votes on executive compensation is expected at the 2031 Annual Meeting of Stockholders.

Key Dates

Recommendation

The filing presents a mixed outlook. While the company is taking steps to strengthen corporate governance (e.g., clawback policy, anti-hedging policy) and strategically refreshing its board with representatives from a significant investor, the financial performance for 2024 (net loss, no executive bonuses) is concerning. The proposed significant increase in the equity incentive plan, leading to substantial potential dilution, is a notable negative. A seasoned investor would likely 'hold' to observe if the governance improvements and strategic board changes translate into improved financial performance and if the dilution is justified by enhanced talent retention and growth, while acknowledging the current financial headwinds and dilution risk.

Keywords

Equity Incentive Plan, Proxy Statement, Corporate Governance, Executive Compensation, Director Elections, Stockholder Meeting, Dilution, Medical Device, SEC Filing, Risk Management